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Pancreatic neuroendocrine tumors: classification and TNM staging 
Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous group of relatively 
rare neoplasms whose yearly incidence is 1 case/100,000 people and represent 
approximately 1-2% of all pancreatic tumors [1]. Although uncommon, they represent a 
disease with growing incidence and high prevalence [2]. This phenomenon probably 
reflects either a higher knowledge of this tumor type by the pathology or the wider 
availability of suitable and efficient radiological and nuclear medicine diagnostic tools 
[3]. The incidence in relatively old autopsy studies has been reported as high as 1.5%, 
even if in these reported series the tumors were clinically unrecognized, often 
asymptomatic and usually small (<1 cm in size) lesions. 
PanNETs show no significant gender predilection and occur at all ages, with a 
peak incidence between 30 and 60 years [4-6]. Although most PanNETs occur 
sporadically, approximately 5-10% of these neoplasms have a hereditary background 
and they may be a part of two main hereditary syndromes: MEN-1 syndrome (Multiple 
Endocrine Neoplasia, Type 1) and VHL syndrome (Von Hippel Lindau).  
Since the beginning of the last century, when the first report of a tumor believed to 
originate from the endocrine pancreas was published [7], several investigators have tried 
to elucidate the clinico-pathological and molecular characteristics of these neoplasms. 
Because different methodological approaches have been used to classify these tumors, a 
variety of nomenclatures have been proposed and they often created some 
misunderstanding  among pathologists and clinicians [8]. 
Clinically, the most used classification of PanNETs is based on the 
presence/absence of abnormal hormone production and this approach identifies two 
broad categories of functioning or nonfunctioning tumors. Nearly 30-40% of PanNETs 
are not hormone-producing and are classified as “nonfunctioning ” and are typically 
diagnosed when their sizes cause compression or invasion of adjacent organs or when 
they give rise to liver or lymph node metastases. Conversely, the remaining 60-70% of 
PanNETs are classified as “functioning” and include preferentially insulinomas, 
glucagonomas, somatostatinomas, gastrinomas and VIP-omas (Table 1). 
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Table 1. Functional Classification of PanNETs [1] 
In 1995, a group of endocrine pathologists [9] proposed a revised classification of 
neuroendocrine tumors of the lung, gut and pancreas. The purpose of this classification 
was to identify clinical and morphological features that were helpful in delineating 
categories of tumors with different prognoses. The criteria proposed by the international 
group of pathologists in 1995 together with various more reliable prognostic parameters 
identified in the last years [10-16], represented the basis for the 2010 WHO 
classification of PanNETs [17].  
Currently, the general histological classification of PanNETs comprises the two 
major categories of well/moderately differentiated and poorly differentiated PanNETs. 
Although several clinico-pathological features (presence and type of the endocrine 
syndrome, tumor size, invasion of nearby tissue,  pattern of growth with prevalence of 
broad solid areas, presence of necrosis, cellular atypia, high proliferative index, vascular 
invasion, and presence of bands forming fibrosis) have been demonstrated to correlate 
with tumor aggressiveness and patients’ prognosis, in the more recent WHO 
classification of PanNETs they are divided into three main categories on the basis of the 
mitotic count and Ki67 proliferative index [18].  PanNET G1 are characterized by low 
mitotic and proliferative status (< 2 mitoses X 10 HPF, and < 2% Ki67 index), PanNET 
G2 by mitotic count between 2 and 20 mitoses X 10 HPF and Ki67 index between 3% 
and 20%. Poorly differentiated neuroendocrine carcinomas, now simply defined as 
neuroendocrine carcinomas (NEC, G3), show a high proliferation including > 20  
mitoses X 10 HPF and > 20% Ki67. From a morphological point of view, PanNET G1 
and G2 are characterized by tumor cell monomorphism, absent or mild nuclear atypia, 
together with the frequently observed trabecular structure. NECs show a mostly solid 
 %  Type  Behavior   
5 - 10  Nonfunctioning, clinically silent   Mostly benign   
50  Insulinomas   90% benign   
20  Other functioning tumors: gastrinoma,  
glucagonoma, somatostatinoma,  
carcinoid, Cushing’s tumors, etc   
50 - 90% malignant   
low grade  
20  Nonfunctioning, locally   symptomatic  
tumors  
70 - 80% malignant   
low grade  
1 - 5  Small cell carcinoma with poor endocrine  
differentiation   
All malignant, high grade   
  
INTRODUCTION 
4 
structure either organized in large, poorly defined aggregates often with central 
necrosis, or diffuse sheets of cells with multiple minute foci of necrosis. They are highly 
invasive, invariably presenting with  metastases to lymph nodes, liver and distant organs 
(Figure 1). 
 
    A     B 
 
Figure 1: A) Glucagonoma of the pancreas: tumor cells are well differentiated and form trabecular 
structures. B) Poorly differentiated endocrine carcinoma of the pancreas composed of cells with severe 
nuclear atypia forming solid sheets. On the left top an area of necrosis is well evident. 
 
In addition to the WHO classifications, a TNM staging must be included in routine sign 
out of PanNETs (Table 2).  A TNM staging system for neuroendocrine neoplasms of the 
pancreas was proposed for the first time in 2006 by the European Neuroendocrine 
Tumor Society (ENETS) [19]. More recently, the International Union for Cancer 
Control developed a TNM staging system, which is now endorsed by both the American 
Joint Cancer Committee and the World Health Organization (UICC/AJCC/WHO 2010 
TNM) [17, 20, 21]. Table 2 summaries T and stage definitions according to ENETS and 
to UICC/AJCC/WHO. The presence of two different TNM systems raised concerns of 
potential confusion in patient management [22, 23]. Recently, Rindi et al. suggested the 
ENETS TNM staging is superior to the UICC/AJCC/ TNM staging system and support 
its use in the clinical practice [24]. 
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Table 2. T and stage definitions in the European Neuroendocrine Tumor Society 
(ENETS) and the International Union for Cancer Control/American Joint Cancer 
Committee/World Health Organization (UICC/AJCC/WHO) 2010 TNM staging system 
[24] 
 
Legend:  NA= not applicable 
  
Definitions ENETS TNM UICC/AJCC/WHO 2010 TNM 
T definition   
T1 Limited to the pancreas, < 2 cm Limited to the pamcreas, <=2 cm 
in greatest dimension 
T2 Limited to the pancreas, 2-4 cm Limited to the pancreas, >2 cm in 
greatest dimension 
T3 Limited to the pancreas, >4 cm or 
invading duodenum or bile duct 
Beyond the pancreas but without 
involvement of the superior 
mesenteric artery 
T4 Tumor invading adjacent organs 
(stomach, spleen, colon, adrenal 
gland) or the wall of large vessels 
(celiac axis or the superior 
mesenteric artery) 
Involvement of the celiac axis or 
the superior mesenteric artery 
(unresectable tumor) 
Stage definition  NA 
Stage I T1, N0, M0 NA 
Stage IIa T2, N0, M0 NA 
Stage IIb T3, N0, M0 NA 
Stage IIIa T4, N0, M0 NA 
Stage IIIb Any T, Any N1, M0 NA 
Stage IV Any T, Any N, M1 NA 
Stage IA NA T1, N0, M0 
Stage IB NA T2, N0, M0 
Stage IIA NA T3, N0, M0 
Stage IIB NA T1-T3, N1, M0 
Stage III NA T4, Any N, M0 
Stage IV NA Any T, Any N, M1 
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Molecular genetics of sporadic PanNETs 
Genetic abnormalities have been investigated to elucidate the pathogenesis of PanNETs 
as well as to identify new biological markers with diagnostic and clinical value.  
For hereditary PanNETs, alterations of MEN1, VHL, TSC2 and NF1 are the main factors 
that drive tumorigenesis. The genetic defect causing each of these inherited PanNET 
syndromes has been elucidated and considerable advances have been made in 
understanding the cellular roles of the various altered proteins [25].  
In contrast, the genetic alterations involved in the onset and progression of 
sporadic PanNETS are poorly understood, although in recent years several studies have 
been carried out to gain insights into the genetic basis of these tumors. To date, two 
main approaches have been used to study sporadic PanNETs: 1) mutation analysis of 
the susceptibility genes associated with hereditary PanNETs or screening of the most 
commonly mutated genes in pancreatic ductal adenocarcinomas (PDACs); 2) study of 
chromosomal gains and losses to identify candidate loci involved in the development of 
these tumors. In Table 3 we summarize a comprehensive review of the papers so far 
published on this subject. 
Several studies demonstrated that approximately 20-40% of sporadic PanNETs 
had somatic inactivating mutations in MEN1, which encodes menin, a component of 
histone methyltransferase complex [26-33]. MEN1 mutation was frequently associated 
with gastrinoma and glucagonoma, but was rare in insulinoma and nonfunctioning  
PanNETs. Recently, whole-exome sequencing of PanNETs confirmed that MEN1 is the 
most frequently mutated gene in these tumors [34]. In addition this study demonstrated 
that PanNETs exhibited frequent mutations in other genes involved in chromatin 
remodeling complex such as DAXX (death-domain-associated protein) and ATRX 
(α−thalassemia/mental retardation syndrome X-linked). Overall, somatic mutations in 
PanNETs were identified in MEN1 (44%), DAXX (25%), ATRX (18%), PTEN (7.3%), 
TSC2 (8.8%), PIK3CA (1.4%). Other oncosuppressor genes such as VHL, RB1, BRCA2 
[35-41] and common oncogenes including myc, fos, c-erbB-2 and sis [42-45] have been 
examined in PanNETs but no genetic alterations were observed. 
Exome sequencing of PanNETs demonstrated that there were important 
differences between the genetic landscapes of PanNETs and those of pancreatic ductal 
adenocarcinomas (PDACs). First, there were 60% fewer genes mutated per tumor in 
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PanNETs than in PDACs, with a mean of 16 mutations per tumor among PanNETs. 
Second, the genes most commonly affected by mutations in PDACs (KRAS, TGF-β 
pathway, CDKN2A and TP53) were rarely altered in PanNETs and vice versa. Third, 
the spectrum of mutations in PDAC and in PanNET was different, with C-to-T 
transitions more common in PDACs than in PanNETs and C-to-G tranversions more 
common in PanNETs than in PDACs. This suggests that mutations in PanNETs and 
PDACs arise through different mechanisms, perhaps because of exposure to different 
environmental carcinogens or through the action of different DNA-repair pathways. 
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Table 3. Summary of gene mutations and losses of putative Tumor Suppressor Genes in 
PanNETs.  
MUTATIONAL ANALYSES 
GENE Mutation 
  
Range % References 
MEN-1 gene (11q13) mutation 78/285 (27%) 0-50% [26-34] 
DAXX gene (6p21.3) mutation 37%  [34] 
ATRX gene (Xq21.1) mutation 18%  [34] 
PTEN gene (10q23) mutation 9/101 (9%) 7-13% [34, 46] 
TSC2 gene (16p13.3) mutation 9%  [34] 
PIK3CA gene (3q26.3) mutation 1.4%  [34] 
VHL gene (3p25.3) mutation 0/39 (0%)  [34, 35, 38, 39] 
RB1 gene (13q14.2) mutation 0/39 (0%)  [37] 
BRCA2 gene (13q12-q13) mutation 0/5 (0%)  [40] 
TP53 gene (17p13.1) mutation 2/39 (4%) 0-5% [41, 47-51] 
KRAS (12p12.1) gene mutation 0/80 (0%)  [34, 47, 50-52] 
CDKN2A (9p21) p16 gene mutation 0/14 (0%)  [51, 53-55] 
DPC4/SMAD4 gene (18q21.1) mutation 0/45 (0%)  [51, 56-58] 
TIMP-3 gene (22q12.3) mutation 2/31 (5%) 0-5% [34, 59] 
HDAC II gene (6q21) mutation 0/10 (0%)  [60] 
CDKN2B p15 gene mutation 0/18 (0%)  [61] 
Other common oncogenes myc, fos, c-erbB-2 
  
0% [50, 51, 62] 
CHROMOSOMAL ABNORMALITIES 
CHROMOSOMAL POSITION Loss 
 
 
Range % References 
1p 55/351 (16 %) 4-44% [63-71] 
1q 31/221 (15%) 4-44% [63, 67, 68, 71-73] 
2p-2q 61/372 (17%) 4-44% [63, 65, 67, 68, 70-72] 
3p 215/620 (35%) 5-100% [35-37, 39, 41, 58, 63, 65-68, 70, 72-78] 
3q 24/191 (13%) 4-40% [36, 63, 72, 73, 75, 76] 
4p-4q 10/212 (5%) 0-5% [63, 66, 68, 75] 
5q 2/44 (5%) 0-14% [66, 68, 75, 79] 
6p 16/184 (9%) 5-20% [63, 68, 70, 72, 73, 76] 
6q 110/331 (33%) 6-66% [36, 63, 65, 67-69, 71, 72, 76, 80] 
7q 3/77 (4%) 0-11% [41, 63, 68, 73] 
8p-8q 23/289 (8%) 4-40% [63, 65, 66, 68, 70, 72, 76] 
9p-9q 26/234 (11%) 0-57% [53-55, 61, 63, 67, 68, 70, 73, 75, 81] 
10p-10q 45/278 (16%) 6-44% [46, 63, 66-68, 70, 72, 76] 
11p 54/294 (18%) 4-54% [63, 65, 67-69, 71, 75, 76] 
11q 178/596 (30%) 4-73% [26, 30, 36, 41, 58, 59, 63, 65-67, 69-73, 75, 76, 82, 83] 
12p-12q 10/126 (8%) 0-6% [63, 68, 71, 75] 
13p-13q 8/187 (4%) 0-15% [35, 37, 41, 63, 65, 68, 72, 75] 
15q 22/148 (15%) 0-27% [36, 63, 70-72] 
16p-16q 52/290 (18%) 4-40% [63, 65, 66, 70-72, 75, 84] 
17p-17q 15/85 (18%) 6-35% [41, 63, 66, 67] 
18p-18q 47/395 (12%) 
 
0-27% [41, 56-58, 63, 65-68, 70, 73, 75, 84, 85] 
19p-19q 1/40 (3%) 0-3% [66, 75] 
20q 8/41 (20%) 20-50% [65, 67] 
21p-21q 26/80 (32%) 12-47% [63, 67, 70, 72] 
22p-22q 93/320 (29%) 0-96% [36, 63, 66, 68-73, 75, 86, 87] 
Xp 39/231 (17%) 4-32% [63, 65, 71, 76, 88] 
Xq 35/220 (16%) 4-27% [63, 69, 71, 76] 
Y LOH 22/84 (26%) 7-45% [63, 69, 76] 
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In recent years, comprehensive genome-wide approaches such as Comparative Genomic 
Hybridization (CGH), high resolution allelotyping and gene expression analyses have 
revealed candidate loci for genes involved in the development of PanNETs but these 
have not been substantiated through genetic or functional analyses. 
Most of the genome-wide studies demonstrated that genetic alterations seem to 
accumulate during tumor progression: the total number of genomic changes per tumor 
appears to be associated with both the tumor size and the stage of the disease [69]. 
These results point toward a tumor suppressor pathway impairment and chromosomal 
instability as important mechanisms associated with malignancy in PanNETs. The 
alterations described are not randomly distributed on chromosomes but are particularly 
common in distinct chromosomal regions. Gains are common on 4pq (17% of the 
tumors) 5q (25%), 7pq (41%), 9q (28%), 12q (23%), 14q (32%), 17pq (31%) and 20q 
(27%), whereas genomic losses frequently occur on 1p (16%), 3p (35%), 6q (33%), 
10pq (16%), 11q (30%), Y (26%) and X (17%).  
Loss of heterozygosity studies on PanNETs indicated different chromosomal 
regions such as 1p, 3p, Xp and 6q, whose deletion is associated with more aggressive 
behavior [35, 47, 63, 68, 76]. Allelic deletion on 11q is frequently found in sporadic 
PanNETs [28, 31, 67] and combining data from all studies referred, it appears that the 
LOH rate is usually 2-3 times higher than the frequency of mutations of the MEN1 
gene.  
Some differences have been reported among PanNETs considering both type 
and number of DNA alterations. Insulinomas exhibit a lower number of genomic 
alterations than other PanNETs and they frequently show gain of 9q32 and loss of 
22q13.1, which appear to be early genetic events in these tumors [71]. By contrast, they 
rarely show 3p and 6q losses associated with malignancy [77, 80]. Malignant 
insulinomas, in contrast, harbor a large number of chromosomal alterations similar to 
that seen in other types of malignant PanNETs [49]. In pancreatic gastrinomas, only 
limited chromosomal imbalances are encountered. Losses at 3p and 18q21 occur in 
approximately 33%  and 22% of cases, respectively [65, 69].  
Nonfunctioning PanNETs (NF-PanNETs) in general harbor higher numbers of 
chromosomal gains and losses than functioning tumors. These genetic aberrations occur 
in chromosomal loci frequently involved in malignant tumors [73]. In a recent high 
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resolution allelotyping analysis of only NF-PanNETs, Rigaud et al.. [67] underlined the 
existence of two different allelotypes among NF-PanNETs: one aneuploid or multiploid 
with a high degree of large chromosomal allelic deletions and the second, diploid, 
showing a small number of scattered losses with no apparent specific localization. In 
this study, survival analysis showed that no specific chromosomal alteration was 
associated with outcome, whereas ploidy status is an independent factor adding 
prognostic information to that given by the proliferative index evaluated with Ki67 
immunohistochemistry. 
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DNA methylation changes in PanNETs 
Malignant cells show major disruptions in DNA methylation patterns when compared 
with normal cells [89]. The pattern of DNA methylation changes substantially when 
cells became malignant, as a result of two major phenomena. Firstly, global genomic 
hypomethylation has been linked to the induction of chromosomal instability and 
hypothesized to contribute to oncogenesis by activation of oncogenes (such as c-MYC 
and H-RAS), and of latent retrotrasposons [90, 91]. Secondly, hypermethylation of 
tumor-suppressor genes contributes to a selective advantage of the cancer cell and 
therefore may represent one of the steps in the sequence of events leading to 
malignancy. DNA methylation patterns are becoming increasingly attractive tools in the 
management of cancer patients. DNA methylation is being examined as a powerful 
markers for early diagnosis of cancer, and for disease monitoring during and after 
treatment [92-98]. DNA methylation patterns change during the process of 
tumorigenesis and these changes appear to be events contributing directly to the 
transformed phenotype [99]. Promoter hypermethylation has been shown to be 
associated with adverse prognosis in a variety of malignancies, including prostate, 
colon, breast, non-small cell lung cancer, and non-Hodgkin lymphoma [100-103].  
To date very few studies have been published about DNA methylation changes 
in PanNETs and there is no information about the role of gene promoter-specific 
hypermethylation as well as global hypomethylation in the development and 
progression of these tumors.  
Much of what is known today about this subject was gained through studies 
focused on aberrant hypermethylation of single or few candidate genes. Several specific 
CpG-island-associated genes are frequently methylated in PanNETs, namely RASSF1A, 
CDKN2A, HIC1, RARβ, APC, MGMT, ER [78, 79, 104-107]. The cumulative 
methylation frequency ranges from only a few percent to more than 70% for some of 
these genes. These methylation rates often differ substantially depending on the study 
population, tumor histology, and/or methodology used to assess CpG island 
methylation. In table 4 we provide a brief overview of the current literature 
summarizing the panel of genes investigated, the methylation rates and the methods 
used.  
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RASSF1A gene silencing by DNA methylation has been reported as a major event in 
PanNETs with methylation rates ranging from 63% to 100% [78, 79, 104-107]. This 
gene works as tumor suppressor in the RAS pathway, regulating proliferation, inducing 
apoptosis and stabilizing microtubules [108-110]. Ras-association domain family 1 gene 
has seven isoforms produced by alternative splicing and expressed from two different 
promoters. Recently, Malpeli et al.. demonstrated that the isoform RASSF1A is down 
regulated in PanNETs compared to normal pancreas and that the overall extent of 
RASSF1A methylation in PanNETs correlated inversely with its expression [104]. 
Moreover, some authors reported the common occurrence of RASSF1A methylation in 
normal pancreas adjacent to PanNETs suggesting that epigenetic change might arise 
early in the onset of PanNETs [111-113].  
Another gene frequently investigate in PanNETs for methylation status is 
CDKN2A [53, 54, 61, 79, 105, 106, 114, 115], a cyclin dependent kinase 4 inhibitor that 
causes retinoblastoma protein to stay in its active form and arrest the cell cycle at G1-S 
transition. Muscarella et al.. [53] reported the presence of CDKN2A/p16 promoter 
hypermethylation or homozygous deletion in a limited number of pancreatic 
gastrinomas and in nonfunctioning PanNETs (a total of 14 cases investigated). These 
data were confirmed by Lubomierski et al.. [81] who reported loss of expression of at 
least one of the tumor suppressor genes CDKN2A/p16, CDKN2B/p15 and 
CDKN2D/p14 localized as a gene cluster at 9p21. mRNA transcripts of these genes 
were lost most frequently in nonfunctioning PanNETs (57%) and less commonly in 
insulinomas (30%) and gastrinomas (22%). 
Arnold et al.. [79, 107] reported high frequency of epigenetic inactivation of 
HIC-1 (Hypermethylated In Cancer 1) ranging from 83% to 93%. HIC-1 encodes a 
zinc-finger transcriptional factor [116] that regulates p53-dependent apoptotic DNA-
damage response [117]. The role of HIC-1 as a TSG is not completely understood and 
further studies are needed to elucidate its function in the pathogenesis of PanNETs. 
Although most of the analyses of DNA methylation patterns in PanNETs were single-
gene studies, three studies analyzed the methylation status of many genes in order to 
define a methylation profile of these tumors [105, 107, 114]. In the first study, Chan et 
al. [114] analysed the methylation status of 14 genes in 11 PanNETs and in 16 
gastrointestinal neuroendocrine tumors demonstrating different methylation profiles in 
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the two subsets of tumors. House et al. [105] investigated aberrant methylation of 11 
candidate tumor suppressor genes in forty-eight PanNETs and found hypermethylation 
of at least one gene in 87% of PanNETs. In decreasing order of frequency, the five most 
commonly methylated genes were: RASSF1A (75%), CDKN2A (40%), MGMT (40%), 
RAR-β (25%), and MLH1 (23%). Moreover, the authors demonstrated that aberrant 
methylation of 3 or more genes predicted both decreased patient survival at 5 years and 
tumor recurrence within 24 months from the time of surgery. In agreement with these 
results, Arnold et al.. [107] analysed the methylation status of 11 genes in 46 PanNETs 
confirming that hypermethylation of tumor suppressor genes was more common in 
PanNETs with high proliferation index (Ki67>10%) and that a CpG island methylator 
phenotype (CIMP phenotype) [118] showed a trend towards worse survival. 
Besides gene-specific methylation, global hypomethylation in PanNETs and 
gastrointestinal neuroendocrine tumors has been recently investigated [119, 120] using 
LINE-1 methylation status as a surrogate marker for genome-wide methylation. These 
studies showed that LINE-1 hypomethylation is common in neuroendocrine tumors 
compared with normal tissue  and is associated with malignant behavior. 
INTRODUCTION 
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Table 4 Review of gene promoter-specific hypermethylation in PanNETs. 
Gene Frequency of gene methylation (%) Range Methods References 
RASSF1A 125/161 (77.6%) 63% - 100% M/P [78, 79, 104-107] 
CDKN2A(p16) 32/135 (23.7%) 0% - 75% M [53, 54, 79, 105, 106, 114, 115] 
HIC1 48/52 (92%) 83% - 93% M [79, 107] 
APC 39/104 (37.5%) 21% - 70% M [79, 105, 107] 
MGMT 33/131 (25.2%) 0% - 40% M/C [79, 105-107, 114] 
MLH1 11/58 (19%) 0% - 23% M [79, 89] 
TIMP-3 8/112 (7.1%) 0% - 44% M [59, 105, 107] 
MEN1 10/55 (18.2%) 11% - 19% M [79, 107] 
CDKN2A(p14) 8/75 (10.7%) 0% - 44% M [105, 106, 114] 
RARb 12/59 (20.3%) 0% - 25% M/C [105, 114] 
CDH1 12/92 (13%) 2% - 23% M [105, 107] 
ER 7/11 (64%) 64% M/C [114] 
P73 8/48 (17%) 17% M [105] 
CDKN2B(p15) 2/18 (11%) 11% P [61] 
COX2 1/11 (9%) 9% M/C [114] 
THBS1 1/11 (9%) 9% M/C [114] 
RUNX 3/46 (7%) 7% M [107] 
VHL 2/35 (6%) 6% M [38] 
GSTp 0/48 (0%) 0% M [105] 
PTEN 0/48 (0%) 0% M [107] 
 
Legend: M: Methylation Specific PCR (MSP); C: COBRA; P: Pyrosequencing 
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The aims of our work were to investigate the occurrence and relevance of gene 
promoter-specific hypermethylation and global hypomethylation in 58 PanNETs in 
order to correlate the methylation profiles with DNA copy number alterations (CNAs) 
and with the clinico-pathologic features of the tumors. 
 
In particular our purposes were: 
1. To study the methylation status of 33 tumor suppressor genes and copy 
number alterations (CNA) of 53 genes in an archival series of formalin fixed 
and paraffin embedded (FFPE) tumor tissues by MS-MLPA (Methylation-
specific multiplex ligation-dependent probe amplification).  
2. to validate MS-MLPA results for the methylation status of MLH1, MGMT, 
THBS1, WT-1, CASP-8, and CDKN2A (p16) genes using additional 
independent techniques (methylation specific PCR (MSP), bisulfite 
pyrosequencing and bisulfite cycle sequencing) to test the robustness of MS-
MLPA assay in gene hypermethylation analyses. 
3. To optimize and apply a quantitative bisulfite pyrosequencing assay to 
measure CpG methylation of Long Interspersed Nuclear Elements -1 (LINE-
1) in order to evaluate the occurrence of global DNA hypomethylation in 
PanNETs compared with normal pancreas. 
4. To evaluate whether a Two dimensional unsupervised hierarchical clustering 
can help to define gene promoter specific hypermethylation profiles of 
PanNETs. Moreover we verified if a small subset of hypermethylated 
markers led to identify specific methylation profiles of PanNETs by using 
Receiver Operator Characteristic (ROC) curves. 
5. To correlate DNA hypermethylation clusters with LINE-1 hypomethylation, 
DNA CNAs and with the clinic-pathologic features of the tumors in order to 
define clinic-pathologic and molecular subsets of PanNETs. 
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Case selection 
Surgical specimens of 58 well characterized pancreatic neuroendocrine tumors 
(PanNETs) encompassing all the main histologic and functional types (Table 5) were 
selected from our previously-reported series of 155 tumors [13]. Selection depended on 
the availability of enough material to perform molecular analyses coupled with 
complete clinicopathologic information including age, endocrine and non endocrine 
symptoms, tumor size, mitotic and Ki67 proliferative index, vascular and perineural 
invasion, presence of metastases at the time of diagnosis, evidence of local invasion at 
surgery, perioperative mortality, and evidence of local recurrence or distant metastases 
during follow-up.  Tumor grade and stage were performed according to the ENETS 
scheme [18, 19]. This study was performed in agreement with the clinical standards laid 
down in the 1975 Declaration of Helsinki and its revision in 1983, and according to the 
rules of the Ethics Committee of the Ospedale di Circolo, Varese, Italy. 
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Table 5. Main clinicopathologic features of PanNETs 
Number of cases 58 
Gender  
Male 29 
Female 29 
Age (years)  
Mean 49 
Range 18-79 
Diameter (cm)  
Mean 4.7 
Range 0.3-18 
Site°  
Head 21 
Body 18 
Tail 12 
Genetic  
MEN1 2 
Sporadic 56 
Syndrome  
Nonfunctioning 28 
Insulinoma 23 
Glucagonoma 2 
Zolliger Ellison 2 
VIPoma 2 
Cushing 1 
Grading  
G1 28 
G2 30 
G3 0 
Angioinvasion  
Absent 26 
Present 31 
Neuroinvasion  
Absent 23 
Present 15 
Staging*  
Stage I 7 
Stage II 20 
Stage III 12 
Stage IV 7 
Follow-up^  
AFD 37 
AWD 6 
DOD 12 
DOC 1 
  
°: for 8 cases information regarding site was not available; *: for 12 enucleated tumors lymph nodes were 
not available for histologic evaluation so the pN was not detected; ^ two patients died immediately after 
surgery. MEN 1= multiple endocrine neoplasia syndrome type 1, AFD: alive freed from disease, AWD= 
alive without disease, DOD= dead for disease, DOC= dead for other causes   
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DNA extraction and evaluation of amplifiability 
DNA samples were obtained from FFPE tissues using representative 8-µm sections. 
Three sections of every specimen were treated twice with xylene, and then washed 
twice with ethanol. DNA was extracted using QIAamp® DNA FFPE Tissue kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Neoplastic areas 
were manually microdissected for DNA extraction and contained at least 70% of tumor 
cells, to minimize contamination by normal cell. Each DNA sample was evaluated for 
integrity and amplifiability by BIOMED-2 multiplex PCR in order to correlate DNA 
fragmentation with MS-MLPA reproducibility. Briefly, as illustrated in Figure 2 five 
pairs of control gene PCR primers were used to amplify products of exactly 100, 200, 
300, 400 and 600 bp from the following four target genes: TBXAS1 (exon 9), RAG1 
(exon 2), PLZF (exon 1), AF4 (exon 11), AF4 (exon 3). DNA fragmentation and MS-
MLPA reproducibility were correlated (data not shown). Only with at least 200 bp 
fragmentation showed reproducible results and were used in MS-MLPA analysis.  
 
 A                 B 
 
Figure 2: Control multiplex PCR for the assessment of amplifiability and integrity  of DNA samples from 
FFPE tissues. A) Schematic diagram of five control genes and the five primer sets for obtaining PCR 
products of 600, 400, 300, 200 and 100 bp. B) FFPE DNAs (S1-S6) generated PCR products ranging 
from 200 to 300 bps. This result illustrates the average level of amplifiability of FFPE DNAs observed in 
our study. 
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Methylation-specific multiplex ligation-dependent probe amplification 
(MS-MLPA) analysis 
MS-MLPA analysis was performed on all the 58 PanNETs reported in Table 1 using the 
ME001 MS-MLPA Tumor suppressor-1 Kit and the ME002 MS-MLPA Tumor 
suppressor-2 Kit (MRC-Holland, Amsterdam, The Netherlands). Using these two kits a 
total of 33 tumor suppressor genes were analysed for aberrant promoter methylation and 
53 genes for copy number alterations (CNAs). All these genes are frequently silenced 
by methylation in tumors of different sites as well as they harbour frequently genetic 
alterations during tumorigenesis. Table 6 lists all the genes examined for the 
methylation analysis and for copy number analysis and reports their chromosomal 
position, sequence accession number and the amplicon size obtained by MS-MLPA 
analysis.  
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Table 6. List of the genes examined by MS-MLPA analysis 
Legend: All the 53 genes were analyzed for copy number alterations. Gene names in bold highlight the 33 
genes analysed for aberrant methylation. (*): PCR products obtained with ME001- MS-MLPA kit; (**): 
PCR products obtained with ME002- MS-MLPA kit;  Twenty-five genes were examined with at least two 
MS-MLPA probes, due to a partial overlapping between the probe mixes contained in the two kits. For 
these genes a mean value of raw MS-MLPA results was calculated. 
Number Gene Chromosomal position Reference sequence Amplicon size 
1 TP73 1p36.3 NM_005427.2 400*, 238** 
2 MSH6 2p16 NM_000179 328** 
3 CASP8 2q33-q34 NM_001080125.1 265* 
4 FHIT 3p14.2 NM_002012 409* 
5 MLH1 3p22.3 NM_000249 167*, 463* 
6 RASSF1 3p21.3 NM_007182 328*, 382* 
7 CTNNB1 3p21 NM_001904.3 472* 
8 RARB 3p24 NM_000965 193*, 453** 
9 VHL 3p25.3 NM_000551 355*, 265** 
10 CASR 3q21.1 NM_000388.3 483*, 483** 
11 IL-2 4q26-q27 NM_000586 445** 
12 APC 5q21-q22 NM_000038 148*, 337** 
13 ESR1 6q24-q27 NM_000125 373*, 301** 
14 PARK2 6q25.2-q27 NM_4562.2 154* 
15 CDK6 7q21-q22 NM_001259.6 310*, 310** 
16 CFTR 7q31-q32 NM_000492 154** 
17 PAX5 9p13.2 NM_016734 208** 
18 CDKN2A (p14) 9p21 NM_058195.2 161* 
19 CDKN2A (p16) 9p21 NM_058195 427** 
20 CDKN2B 9p21 NM_004936.3 211* 
21 DAPK1 9q34.1 NM_004938 346* 
22 PTCH1 9q22.1-q31 NM_000264 175** 
23 CELF2 10p13 NM_015413.1 364* 
24 CREM 10p12.1-p11.1 NM_181571.1 136*, 136** 
25 PTEN 10q23 NM_000314 292*, 183**, 373** 
26 MGMT 10q26 NM_002412 191**, 346** 
27 CD44 11p13 NM_000610 319*, 462** 
28 WT1 11p13 NM_000378 247** 
29 PAX6 11p13 NM_001604 409** 
30 GSTP1 11q13.2 NM_000852 454*, 273** 
31 ATM 11q22-q23 NM_000051 184*, 160**, 418** 
32 CADM1 11q23.2 NM_014333 427*, 364** 
33 CDKN1B 12p13.1-p12 NM_004064 274* 
34 TNFRSF1A 12p13.2 NM_001065.2 175*, 445* 
35 PAH 12q22-q24.2 NM_000277 229*, 229** 
36 CHFR 12q24.33 NM_001161344 238*, 292** 
37 BRCA2 13q12-q13 NM_000059 301*, 418*, 148** 
38 RB1 13q14.2 NM_000321 319**, 472** 
39 MLH3 14q24.3 NM_014381.2 202*, 202** 
40 THBS1 15q15 NM_003246 355** 
41 PYCARD 16p11.2 NM_013258 398** 
42 TSC2 16p13.3 NM_000548 281*, 281** 
43 CDH1 16q22.1 NM_004360.3 337* 
44 CDH13 16q23.3 NM_001257 436*, 219** 
45 PMP22 17p12 NM_000304 256** 
46 TP53 17p13.1 NM_000546 168** 
47 HIC1 17p13.3 NM_006497.3 220* 
48 BRCA1 17q21.31 NM_007294.3 246*, 140** 
49 BCL2 18q21.3 NM_000633.2 256* 
50 STK11 19p13.3 NM_000455 382** 
51 KLK3 19q13.41 NM_145864 390*, 390** 
52 GATA5 20q13.33 NM_080473 434** 
53 TIMP-3 22q12.3 NM_000362 142* 
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MS-MLPA technique was described by Nygren et al. [121] and the main steps of the 
protocol are reported in Figure 3. 
  
 
Figure 3 Diagram of the steps of MS-MLPA procedure. The MS-MLPA procedure can be divided in five 
steps: 1. DNA denaturation and hybridisation of MLPA probes; 2. ligation and digestion; 3. PCR; 4. 
separation of amplification products by capillary electrophoresis and 5. data analysis. 
 
According to the manufacturer’s instructions the probe-mix was added to 50-250 ng of 
denatured DNA (98°C for 5 minutes) and allowed to hybridize for 16 hours at 60°C. 
After hybridization of the MLPA probes to the denatured DNA, the reaction was 
equally divided in two tubes. One tube is designed for the detection of the alterations in 
the copy number and the other tube for analyses of the aberrant DNA methylation. 
Ligase mix was added to the first vial, and Ligase-Digestion mix to the second vial. 
Since the MS-MLPA probes contain a motif for the methylation-sensitive restriction 
enzyme HhaI, the DNA methylation status was determined by restriction digestion by 
addition of HhaI to the second tube.  
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Samples were incubated for 30 minutes at 48°C, then the HhaI enzyme is inactivated by 
denaturation at 95°C for 1 minute. Since the unmethylated sequences are cut by the 
restriction enzyme, this process results in the ligation of the methylated sequences only. 
Eight microliters of the two aliquots are then amplified in a 25 µl of PCR reaction using 
a Veriti thermal cycler (Applied Biosystems, Foster City, USA) with this thermal 
protocol: 35 cycles of denaturation at 95 °C for 30 s, annealing at 60°C for 30 s and 
extension at 72°C for 1 min with a final extension of 20 min at 72°C. Aliquots of 2.5 µl 
of the PCR reaction were combined with 0.5 µl TAMRA internal size standard (Applied 
Biosystems, Foster City, USA) and 13.5 µl of deionized formamide. After denaturation, 
PCR products were separated by electrophoresis on an ABI 310 capillary sequencer and 
Genemapper analysis v.4.0 (Applied Biosystems). Values corresponding to peak size 
(base pairs) and peak height were used for further data processing by Coffalyser V7 
software (MRC-Holland). All MS-MLPA reactions were performed at least two times. 
Copy number analysis was performed using MS-MLPA results from undigested 
samples, comparing each tumor sample with three reference DNA samples (normal 
DNA isolated from leukocytes and included in each analysis). The data generated in the 
undigested sample were first normalised intra-sample by dividing the signal of each 
probe by the signal of every reference probe in that sample, thus creating as many ratios 
per probe as there are reference probes. Relative copy number or Dosage Quotient (DQ) 
was obtained by comparing this ratio with the same ratio obtained from reference DNA 
sample (inter-sample normalisation). Since DQ values obtained with normal DNA 
samples were always between 0.7 and 1.3, loss or gain of a specific region was scored 
in tumor DNAs when DQ was <0.5 or >1.5, respectively. 
The methylation profile of a sample was assessed by calculating a Methylation 
dosage Ratio (MR) following this calculation: MR=(Px/Pctrl)Dig/(Px/Pctrl)Undig where 
Px is the peak area of a given target probe, Pctrl is the sum of the peak areas of all 
control probes, Dig stands for HhaI digested sample, and Undig stands for undigested 
sample. Aberrant methylation was scored as a categorical variable using a specific MR 
threshold for each gene corresponding to the highest level of accuracy of the test, as 
previously reported [122]. 
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Validation of MS-MLPA results 
Validation of MS-MLPA results was possible for MLH1, THBS1, MGMT, WT-1 and 
CASP-8 genes using three different methods commonly employed for DNA methylation 
analysis, namely methylation-specific PCR (MSP) [123] , bisulfite pyrosequencing 
[124] and bisulfite cycle-sequencing [125, 126] on tumor samples from different body 
sites. Table 7 summarizes the sequence of the primers used for DNA methylation 
analyses. designed with the PyroMark Software Assay. 
MS-PCR was applied to analyse MLH1 methylation status following the original 
method developed by Herman et al. [123]. Bisulfite modification of genomic DNA (300 
ng) was performed with an EpiTect Bisulfite Kit (Qiagen, Hilden, Germany) according 
to the manufacturer’s recommendations. Bisulfite-converted DNA was amplified 
separately using the primers specific for methylated and unmethylated sequences of 
MLH1 (Table 7). A single round of fluorescent PCR was performed using 5 µl of the 
bisulfite-converted DNA  in a 15 µl reaction containing 1.5 µl of 10X buffer (Roche, 
Mannheim, Germany), 0.3 µM primer pairs, 200 µM dNTPs and 2U DNA polymerase 
(Roche, Mannheim, Germany). Thermal cycling conditions were: 5 min at 95°C, 10 
cycles of 94°C/50 s, specific T annealing/50 s, 72 °C/50 s and 25 cycles of 89°C/30 s, 
specific T annealing/30 s and 72°C/30 s. The fluorescently labeled PCR products were 
electrophoresed on an Applied Biosystems 310 automated DNA sequencer (Applied 
Biosystems, Milan, Italy) and the fluorescent signals from the differently sized alleles 
were recorded and analyzed using Genescan software (version 2.1) (Applied 
Biosystems, Milan, Italy). All MSP data have been obtained from at least two 
independent modifications of DNA and we scored as positive only signals detectable in 
repeated experiments. Bisulfite pyrosequencing and bisulfite cycle-sequencing were 
used to confirm methylation patterns of  THBS-1, WT-1, MGMT and CASP-8 genes 
using primers designed by PyroMark Assay Software (Table 7). 
PCR products for THBS1 and MGMT genes were analysed by pyrosequencing 
using PyroGold reagents on a PyroMark Q96 ID system (Qiagen). The PCR product 
was bound to Sepharose HP (Amersham Biosciences, Uppsala, Sweden) and the 
Sepharose beads containing the immobilized PCR product were prepared for 
pyrosequencing according to the manufacturer’s instructions. Pyrogram outputs were 
analyzed by the Pyromark Q24 software using the Allele Quantification software 
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(Qiagen) to determine the percentage of methylated alleles at each CpG site. Aberrant 
methylation of THBS1 and MGMT was scored when the mean percentage value of 
methylated alleles was higher than 10%. This threshold value corresponded to the mean 
percentage of methylated alleles plus 3 times the standard deviation observed in 10 
normal unmethylated DNA samples. 
PCR products for WT-1 and CASP-8 genes were analysed by cycle-sequencing 
using Big Dye Terminator mix version 1.1, on ABI 310 (Applied Biosystems, CA, 
USA). Sequencing electropherograms were analysed by Sequencing Analysis software 
(version 5.3, Applied Biosystems, CA, USA).  
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Table 7. Validation of MS-MLPA results using methylation-specific PCR (MSP), bisulfite pyrosequencing, bisulfite cycle-sequencing. 
GENE Method Primer sequences 
Number of 
samples 
examined 
Overall 
concordance with 
MS-MLPA results 
MLH1 
Methylation-
Specific PCR 
(MSP) 
MET-Fw: 5’HEX-ACGTAGACGTTTTATTAGGGTCGC-3’ 
MET-Rv: 5’-CCTCATCGTAACTACCCGCG-3’ 
UNMET-Fw: 5’FAM- TTTTGATGTAGATGTTTTATTAGGGTTGT-3’ 
UNMET-Rv:  5’-ACCACCTCATCATAACTACCCACA-3’ 
102 95% (97/102) 
THBS-1 Pyrosequencing 
Fw: 5’-GTTTATTGGTAGGAGGAATTTTTAGGAA-3’ 
Rv: 5’ biotin -CCCTAAACTCCCAAACCAACTC-3’ 
Seq: 5’-AGGAATGAGAGAGTTTTTTTAAAAG-3’ 
30 90% (27/30) 
MGMT Pyrosequencing 
Fw: 5’biotin-GGATATGTTGGGATAGTT-3’ 
Rv: 5’-AAACTAAACAACACCTAAA-3’ 
Seq: 5’-CCCAAACACTCACCAAA-3’ 
96 96% (92/96) 
WT-1 Cycle Sequencing Fw: 5’-GGTTAAGAAGGGGAGGTGG-3’ Rv: 5’-AACAACCTCCTCTTCAACC-3’ 30 100% (30/30) 
CASP-8 Cycle Sequencing Fw: 5’-TGGAGTTAGTATAAATGTTTTTTAATAAAG-3’ Rv: 5’-ACCCAATTTCCAACCATTCA-3’ 30 100% (30/30) 
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LINE-1 PCR and pyrosequencing 
The methylation status of LINE-1 was evaluated on the 58 PanNETs and eight samples 
of normal pancreas by using bisulfite-PCR and pyrosequencing  LINE-1 assay was 
designed toward a consensus LINE-1 sequence (GenBank accession number M80343.1) 
and allowed to quantify the percentage of 5-methylated cytosines (%5mC) in five 
consecutive CpG sites (Figure 4). PCR was performed in a 50 µl reaction volume that 
included: 2 pmol of forward primer, 2 pmol of reverse biotinylated primer, 5 ul of 
bisulfite-treated genomic DNA, 1.25 Units of GoTaq DNA polymerase, 1X GoTaq 
Flexi Buffer (Promega, Madison, WI, USA), 200 µM dNTPs. Thermal cycling 
conditions were: 3 min at 95°C, 45 cycles at 95 °C/25 s, 50°C/25 s, 72 °C/25 s followed 
by a final extension at 72°C for 5 min.  
Fully methylated and unmethylated DNA (Millipore, Billerica MA, USA) were 
used as positive and negative controls in each experiment. Reproducibility was 
confirmed by analyzing all the samples in duplicate with a maximum of within-sample 
coefficients of variation equal to 5% (range 2%-5%). 
 
 
Figure 4: Diagram of the pyrosequencing assay used to measure LINE-1 promoter methylation in 
PanNETs and samples of normal pancreas. Arrows indicate the sequence and the position of the primers 
used for the bisulfate PCR (145 bp) and pyrosequencing. The percentage of 5-methylated cytosines was 
measured in the five consecutive CpG sites highlighted in red. 
  
LINE-1 5’UTR                                                     3’UTR
6 Kb
AAAAn
TCGTGGTGCGTCGTTTTTTAAGTCGGTTTGAAAAGCGTAA
SEQ.
ORF1 ORF2
GAGTTAGGTGTGGGATATA
AGTTAGGTGTGGGATATAGTT
CCTTTCCCTTAAAAAACTAAAAAC - BIOT
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Statistical analysis 
Methylation matrix was generated codifying as 1/0 the presence/absence of methylation 
of a specific gene in a specific patient. Then, the final matrix has as many rows as the 
number of patients and as many columns as the number of genes. A two way 
agglomerative cluster analysis (on genes and patients) has been performed on this 
matrix using complete linkage and Jaccard index distance metric. Given the 
dichotomous nature of our data Jaccard index was selected as the best dissimilarity 
measure. Three different groups of patients were emerged from the clustering. Chi-
squared tests were applied to identify possible associations between these groups and all 
the clinical variables. To investigate if these three groups had different survival rates we 
performed univariable and multivariate survival analysis. Specifically in the univariable 
case we used Kaplan-Mayer survival curves estimation followed by the log-rank test, 
while in the multivariate analysis we used the Cox’s proportional hazard model. In both 
cases we found a statistically significant difference among groups. Anova test was 
performed to evaluate the difference in the percentage of CNAs and of LINE-1 
methylation among the three groups. 
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Validation of MS-MLPA 
Validation of MS-MLPA results was possible for MLH1, MGMT, THBS1, WT-1, CASP-
8, and CDKN2A (p16) genes, using additional independent techniques: methylation-
specific PCR (MSP), bisulfite pyrosequencing, bisulfite and cycle sequencing. As is 
evident from the comparative analyses reported in Table 7, there was a good 
concordance between MS-MLPA and the other three methods based on bisulfite 
conversion of DNA. In particular, comparing the MS-MLPA and MSP methods, there 
was agreement between the two approaches in 95 % of the samples (97 of 102 cases). 
All five discordant samples showed methylation of MLH1 using MSP but were negative 
in the MS-MLPA analysis. Bisulfite cycle sequencing confirmed MS-MLPA results in 
100 % of tumor samples analyzed for WT-1 and for CASP-8 methylation. Analogously, 
MS-MLPA and bisulfite pyrosequencing showed good concordance in MGMT and 
THBS1 methylation analysis, confirming the same results in 96 % and in 90 % of cases, 
respectively. The only four discordant cases were included among the five discordant 
samples comparing MS-MLPA and MSP methods: they were MSI tumors, negative for 
the protein expression, methylated using MSP method but negative in MS-MLPA 
analysis.  
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DNA hypermethylation profiling identifies different prognostic 
clusters of PanNETs 
MS-MLPA analysis of the 58 PanNETs reported in Figure 5 demonstrated that a subset 
of 16 PanNETs (28%) was characterized by a concerted hypermethylation at a large 
number of genes (more than 25% of the 33 promoters examined) and that this 
phenotype was positively correlated with poor prognosis (p=0.02). Unsupervised 
hierarchical clustering provided the best performance in subtype classification of 
PanNETs distinguishing three specific methylation profiles that were strongly 
associated with prognosis at univariable analysis (p=0.004; Figure 5). Cluster 3 (20 
patients) was positively correlated with poor prognosis compared to cluster 1 and 
cluster 2 (13 and 25 patients, respectively) and showed significant higher levels of 
methylation in the following genes: DAPK1, TIMP3, PAX5, HIC1, CADM1, PYCARD, 
ESR1, VHL, RARB, WT1 (p<0.001). Samples in cluster 1 displayed a very homogeneous 
profile being almost completely unmethylated, while PanNETs in cluster 2 showed high 
frequency of hypermethylation in few genes, such as CASP8, GSTP1 and RASSF1. Of 
note, these three genes were commonly methylated also in cluster 3. 
Receiver operating characteristic (ROC) curves were generated showing the 
sensitivity versus 1-specificity of all the methylated genes in order to define the genes 
that most significantly distinguished PanNETs in cluster 3 from PanNETs in clusters 1 
and 2. The areas under the ROC curves (AUCs) ranged from 0.96 to 1.00 for the best 
combinations of genes (Figure 6). In particular, hypermethylation of  DAPK1, TIMP-3 
and PAX5 exhibited 100% sensitivity and 100% specificity in identifying PanNETs in 
cluster 3.  
We next analysed the clinico-pathological profiles of the three DNA methylation 
clusters and Table 3 summarizes the tumor characteristics in each class. There were no 
statistically significant differences in age, gender, tumor size, proliferation index, degree 
of differentiation among the three clusters. However, consistent with the higher 
mortality of cluster 3 patients, there was a significant difference in the proportion of 
stages IV in cluster 3 compared with cluster 1 and 2 (33% versus 4% of patients, 
respectively; p=0.04) Moreover, cluster 3 included mainly nonfunctioning PanNETs 
and fewer insulinomas compared with cluster 1 and 2 (p=0.08). 
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Figure 5: Unsupervised hierarchical clustering of the 58 PanNETs according to their methylation 
profiles. A) Heatmap with cases orientated along the horizontal axis and genes orientated along the 
vertical axis. B) Kaplan-Meier curve indicating that PanNETs with high levels of gene methylation (more 
than 25% of the 33 promoters examined) show worse prognosis than tumors with low levels of 
methylation (P=0.02). C) Kaplan-Meier curve indicating that Cluster 3 was positively correlated with 
poor prognosis compared to cluster 1 and cluster 2 
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Figure 6: Receiver operating characteristic (ROC) curves were generated to define the genes that most 
significantly distinguished PanNETs in cluster 3 from PanNETs in clusters 1 and 2. Sensitivity, the true 
positive rates, is shown along the y-axis, while specificity, or the false positive rate, is shown along the x-
axis. The calculated AUC is given for each plot in rank order beginning with highest AUC. 
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Table 8. Clinicopathologic features of different cluster tumor groups 
 
 
 No Sex Age  Genetic  Syndrome  Diamerer (cm)  Mit. Ki67 Grading  Staging  Follow-up 
  F/M mean range  MEN1 Sporadic  NF INS GLUC ZES VIP ACTH  mean range    G1 G2 G3  I II III IV  AFD AWD DOD DOC 
                                  
Cluster 1 13 7/6 45 32-65  1 12  5 7 0 0 1 0  3.3 0.3-11  <1 2.9% 8 5 0  1 5 2 0  11 1 1 0 
Cluster 2 25 14/11 50 18-79  1 24  10 12 2 1 0 0  4.8 1.4-18  2.28 4.5% 12 13 0  5 7 7 1  17 4 2 2 
Cluster 3 20 8/12 50 30-76  0 20  13 4 0 1 1 1  5.5 1.5-11  2.4 3.75% 8 12 0  1 8 3 6  9 1 9 1 
                                  
F: female; M: male; NF: nonfunctioning; INS: insulinoma; GLUC: glucagonoma; ZES: Zollinger-Ellison Syndrome; VIP: VIPoma; ACTH: 
Cushing’s syndrome; Mit: mitoses X 10HPF;  AFD: alive free of disease; AWD: alive with disease; DOD: died of disease; DOC: died of other 
cause. 
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DNA hypermethylation clusters and LINE-1 hypomethylation 
We used the quantitative bisulfite pyrosequencing to determine the methylation status of 
LINE-1 repetitive sequences in the 58 PanNETs compared to eight samples of normal 
pancreas (Figure 7). In normal samples little variation in LINE-1 methylation was 
observed. By contrast, PanNETs exhibited a high variability in LINE-1 methylation 
ranging from 44.5% to 70%. Although overall lower levels were observed in tumors 
compared with normal samples (average 60.2 % ± 4.7% versus average 64.3 % ± 0.9 %, 
respectively), differential LINE-1 hypomethylation levels were observed among the 
three hypermethylation clusters of PanNETs as exemplified in Figures 2 and 3. Cluster 
1 was a relatively homogeneous group showing no significant LINE-1 hypomethylation 
compared to normal pancreas. By contrast, both cluster 2 and 3 showed a high 
variability in LINE-1 methylation although important differences were found between 
the two groups. Cluster 2 exhibited the lowest levels of LINE-1 methylation both 
comparing these tumors with normal pancreas (p=0.009) and with PanNETs in cluster 1 
and 3 (p=0.02). Cluster 3 showed on average a modest degree of LINE-1 
hypomethylation. Most tumors in this group showed an increase in LINE-1 methylation 
compared to normal pancreas and only four cases displayed low levels of LINE-1 
methylation similarly to those observed in cluster 2 (Figure 2A). Notably, regardless of 
DNA hypermethylation clusters, decreased levels of LINE-1 methylation were 
significantly correlated with advanced stage (61.7% ± 3.6 in I and II stages versus 
57.4%  ± 5.5 in III and IV stages; p=0.002) and poor prognosis (p<0.0001) (Figure 7B). 
To determine whether LINE-1 methylation status was an independent prognostic factor 
all variables which were significant in univariate analyses, i.e. grading (p=0.01), Ki67 
proliferative index (p=0.02), ENETS Stage (p=0.0002) and DNA hypermethylation 
clusters (p=0.004) were included in the multivariate analysis, which was conducted 
using the Cox proportional hazards model. The analysis revealed that low LINE-1 
methylation status was an independent prognostic factor of poor prognosis (p 0.006), 
instead DNA hypermethylation clusters showed a borderline significance (p=0.08). No 
other independent prognostic factor was found (Table 9). 
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Figure 7: A) Quantitative LINE-1 methylation analysis in normal pancreas and in the three different 
clusters of PanNETs (C1: cluster 1; C2: cluster2; C3: cluster 3). Scatter plot comparison show significant 
lower levels of LINE-1 methylation in cluster 2 compared to normal pancreas (p=0.009) to cluster 1 and 3 
(p=0.02). B) Kaplan Meier surve indicating that decreased levels of LINE-1 methylation are significantly 
correlated with poor prognosis. Patients were stratified into high (H-LINE-1 Meth.) and low (L-LINE-1 
Meth.) groups using 58% as LINE-1 percentage. 
 
 
Table 9. Multivariate analysis for the prognostic significance of clinico-pathologic 
factors and DNA methylation in PanNETs 
Variable HR 95% CI p-value 
LINE-1 methylation 0.18 0.05 - 0.61 0.006 
Methylation clusters 3.00 0.8 - 10.7 0.08 
Ki67 index 1.05 0.9 - 1.2 0.34 
ENETS stage 1.5 0.4 - 5.6 0.50 
Grade 1.2 0.3 – 3.9 0.80 
Legend: CI, confidence interval; HR, hazard ratio 
 
A
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Figure 8: Examples of pyrograms for LINE-1 quantitative methylation analysis in three representative 
cases from the three methylation clusters. At each CpG site the proportion of C (%) after bisulfate 
conversion is reported. The overall LINE-1 methylation level was calculated as the average of the 
proportions of C (%) at the five CpG sites. Black arrows point the internal control cytosine residues that 
check for the adequacy of bisulfate treatment in the pyrosequencing analysis. 
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DNA hypermethylation clusters and CNAs 
CNA analysis at 53 different chromosome loci was possible in 47 PanNETs. An 
average of 14 (27%; range 2% to 51%) probes per sample showed abnormal patterns 
and an overview of the distribution of CNAs is shown in Table 10. A significant higher 
frequency of gains was observed compared with losses (mean number of 14 gains 
versus 1 loss per case, p≤0.001). TIMP-3 was the most frequently affected gene, 
followed by CDKN1B, VHL, PTCH1, CHFR, CADM1, CFTR, STK11, THBS1, p14 
CDKN2A, CDKN2B and PAX6. 
Table 10. Copy number Alteration (CNA) profiles at 53 different chromosome loci of 47 PanNETs  
 
Legend: analytic description of presence (black cells) or absence of CNA (white cells). Genes are sorted 
from right to left according to CNA frequency. For each case LINE-1 Methylation percentage and 
hypermethylation cluster are shown. 
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47 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 1 1 1 1 1 1 -1 -1 -1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 51 61 2
48 -1 -1 -1 -1 -1 -1 1 -1 1 1 1 -1 1 -1 -1 -1 -1 1 -1 -1 -1 1 1 1 -1 -1 -1 -1 1 1 1 -1 1 -1 1 -1 1 1 1 1 1 -1 1 1 -1 1 -1 -1 1 -1 1 1 1 49 61 1
20 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 1 1 -1 1 -1 1 -1 -1 -1 -1 -1 1 1 -1 1 1 1 1 1 -1 -1 1 1 1 1 1 1 1 1 1 1 1 1 47 62 2
30 -1 -1 -1 -1 -1 -1 1 1 -1 1 -1 -1 -1 -1 -1 1 1 -1 -1 -1 1 1 1 -1 1 -1 -1 1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 1 -1 1 1 1 1 1 1 1 1 1 1 1 1 1 47 52 2
1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 1 1 1 1 -1 -1 1 -1 -1 1 1 -1 1 1 1 1 -1 1 1 -1 -1 1 -1 1 -1 1 -1 1 -1 1 -1 -1 1 -1 1 1 1 43 60 3
22 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 1 1 -1 1 -1 1 1 -1 -1 1 1 -1 -1 -1 1 1 1 1 1 1 -1 1 1 -1 1 -1 -1 -1 -1 1 -1 1 1 1 -1 1 1 43 48 2
24 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 1 -1 1 1 1 -1 1 -1 -1 -1 -1 1 1 1 -1 1 1 -1 1 1 1 1 1 1 1 1 1 1 1 43 55 2
49 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 1 1 -1 -1 1 1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 1 1 -1 -1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 43 60 2
39 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 1 -1 -1 -1 1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 1 -1 1 -1 1 -1 1 -1 1 1 -1 1 1 1 1 1 -1 -1 1 1 1 1 1 1 40 59 2
34 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 1 -1 1 1 -1 -1 1 -1 -1 1 1 1 1 -1 -1 -1 -1 -1 1 -1 -1 1 1 1 1 1 1 1 1 1 38 62 2
38 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 1 1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 38 59 2
46 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 1 -1 -1 1 1 -1 -1 1 -1 -1 1 -1 -1 -1 1 -1 1 1 1 1 1 1 1 1 1 1 1 1 1 38 66 3
25 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 1 1 -1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 34 61 2
27 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 1 -1 -1 1 -1 1 1 -1 -1 -1 1 -1 1 1 1 1 1 -1 1 1 1 1 1 1 1 34 60 2
51 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 1 -1 1 1 1 -1 1 1 1 -1 1 -1 1 -1 -1 1 1 -1 -1 -1 -1 -1 -1 -1 1 1 -1 -1 -1 1 -1 -1 -1 -1 -1 1 1 -1 -1 1 -1 34 57 2
14 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 1 -1 1 -1 1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 1 1 1 -1 -1 -1 1 1 -1 -1 1 -1 1 1 1 1 1 30 60 3
33 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 1 1 -1 1 1 1 -1 -1 1 1 -1 1 1 -1 -1 -1 -1 -1 -1 -1 1 1 -1 -1 -1 1 1 1 30 62 1
56 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 1 -1 -1 1 -1 -1 -1 1 -1 -1 1 1 1 1 -1 1 1 1 1 1 1 1 30 65 1
8 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 1 -1 -1 -1 -1 1 -1 -1 1 1 -1 1 -1 1 1 1 -1 1 -1 -1 -1 1 -1 1 1 26 67 3
57 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 1 -1 1 1 1 1 1 1 1 1 1 1 1 26 62 1
58 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 1 -1 1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 1 1 1 1 1 -1 1 1 -1 1 1 -1 1 26 64 1
2 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 1 1 1 1 1 -1 1 1 -1 1 -1 -1 1 -1 -1 1 1 25 64 3
32 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 1 -1 1 1 -1 -1 1 1 1 1 1 1 1 1 1 25 54 2
36 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 1 1 -1 1 1 1 1 1 1 1 1 1 25 64 2
45 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 1 1 1 -1 1 -1 1 1 1 1 1 -1 1 25 57 2
4 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 1 -1 -1 -1 1 -1 -1 1 1 -1 1 1 -1 1 1 -1 -1 -1 -1 1 1 23 60 3
10 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 1 -1 1 1 -1 -1 1 1 -1 -1 -1 -1 -1 -1 -1 1 1 -1 -1 -1 1 1 1 23 53 3
16 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 1 1 -1 -1 1 1 1 1 -1 -1 -1 -1 1 -1 1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 1 1 23 57 3
18 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 1 1 -1 1 1 1 1 1 1 1 23 61 3
37 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 1 -1 1 -1 -1 -1 1 -1 -1 -1 1 -1 1 1 1 1 1 -1 23 61 2
5 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 1 -1 1 -1 -1 -1 1 -1 -1 1 -1 1 -1 -1 1 1 -1 1 -1 -1 -1 -1 -1 1 1 21 65 3
11 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 1 1 1 1 1 1 1 1 1 1 21 62 3
26 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 1 -1 -1 1 1 -1 -1 1 -1 -1 -1 -1 1 -1 -1 -1 1 -1 -1 -1 1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 1 -1 1 -1 -1 -1 21 58 2
28 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 1 -1 1 -1 -1 -1 1 -1 -1 1 -1 -1 -1 1 -1 1 -1 -1 -1 -1 -1 1 1 21 61 2
52 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 1 -1 1 -1 -1 -1 1 -1 -1 -1 -1 -1 1 1 -1 -1 -1 1 -1 1 -1 -1 1 1 -1 1 21 65 1
59 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 1 1 -1 1 1 1 1 1 1 1 21 63 1
55 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 1 -1 -1 -1 -1 -1 1 -1 -1 1 -1 -1 1 1 1 1 1 1 19 56 1
3 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 1 -1 1 1 1 1 1 1 1 17 67 3
6 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 1 -1 1 1 -1 -1 1 1 -1 1 -1 -1 -1 -1 -1 1 1 17 60 3
13 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 1 -1 1 1 -1 -1 1 -1 -1 1 1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 1 -1 17 60 3
29 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 1 -1 1 1 1 1 1 1 1 17 59 2
23 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 1 -1 1 1 -1 1 -1 -1 1 -1 1 1 -1 15 61 1
40 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 1 -1 1 1 1 1 1 -1 1 15 45 2
35 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 1 -1 -1 1 -1 1 1 -1 1 13 61 2
50 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 1 -1 -1 1 1 -1 1 9 60 1
53 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 -1 -1 -1 -1 -1 1 -1 1 -1 -1 -1 6 59 1
17 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 1 2 50 3
CNA % 0 0 0 0 0 2 4 6 6 6 6 6 9 9 9 9 11 13 13 13 13 15 17 19 19 19 21 23 23 23 23 26 26 26 28 28 34 34 34 38 47 51 55 57 57 60 60 64 66 70 72 81 87
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We evaluated the CNA percentages in the three hypermethylation clusters and found 
that cluster 2 PanNETs exhibited significant higher levels of CNAs with respect to 
cluster 1 and 3 tumors (Figure 9A; p=0.02). In particular, CNAs at six specific loci were 
more frequently observed in cluster 2 than in cluster 1 and 3 and included RB1 
(p=0.0002), CADM1 (p=0.0002), PAX6 (p=0.005), PTCH1 (p=0.01), CHFR (p=0.02) 
and THBS1 (p=0.04) (Figure 9B). 
High CNA percentages were positively associated with tumor size (p=0.02), G2 
grading (p=0.02) and Ki67 Index (p=0.04). No other association with clinico-pathologic 
features was observed. 
A) 
 
B) 
 
Figure 9: Copy number alterations (CNA) analysis in PanNETs. A) Scatter plots show significant higher 
CNA percentage in cluster 2 (C2) compared with cluster 1 and 3 (C1 and C3, respectively). B) The 
histogram shows the six chromosomal regions at wich significantly higher CNA frequencies were 
observed in cluster 2 compared to cluster 1 and  3. 
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This is the first work addressing DNA methylation profiling of PanNETs and its 
correlation with CNAs. For this purpose, we chose to study a well-characterized series 
of PanNETs previously examined [13], in order to correlate their clinicopathologic 
profiles and follow up data with specific patterns of both DNA aberrant methylation and 
CNAs. 
 Firstly, our study demonstrates that the simultaneous methylation analysis of a 
large number of tumour suppressor genes with a broad spectrum of cellular functions 
and frequently affected by de novo methylation in cancer is a powerful method for 
classification of PanNETs and allows the identification of specific methylation profiles 
related to different clinical behaviour. In particular, we found that a subgroup of 
PanNETs was characterized by a concerted hypermethylation at multiple loci, 
reminiscent of the CpG island methylator phenotype (CIMP) described in colorectal 
cancers [118]. Even if this phenotype was associated with worse prognosis in our series 
(p=0.02), unsupervised hierarchical clustering analysis provided the best performance in 
subtype classification of PanNETs, resulting in a clear separation into three 
prognostically and biologically different groups. Cluster 1 showed almost complete 
absence of gene methylation while PanNETs in cluster 2 showed high frequency of 
hypermethylation in few genes, such as CASP8, GSTP1 and RASSF1. By contrast, 
cluster 3 displayed a hypermethylated profile compared with the other two groups and 
showed significant higher frequencies of methylation in a large number of genes, 
namely DAPK1, TIMP-3, PAX5, HIC1, CADM1, PYCARD, ESR1, VHL, RARB, WT1 
(p<0.001). Especially in combination, these markers were able to distinguish reliably 
this subset of PanNETs from Cluster 1 and Cluster 2 tumors. In particular, combining 
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DNA hypermethylation of DAPK1, TIMP-3 and PAX5 resulted in both sensitivity and 
specificity of up to 100% in the detection of this specific profile.  
PanNETs in cluster 3 exhibited a more aggressive clinical behaviour than tumours in 
cluster 1 and 2 because they were associated with advanced stage (p=0.04) and poor 
prognosis (p=0.004). Moreover, cluster 3 included mainly nonfunctioning PanNETs and 
fewer insulinomas compared with cluster 1 and 2 (p=0.08). Overall these results 
strongly suggested a role of de novo DNA methylation in the progression of PanNETs 
through simultaneous involvement of multiple genes governing cell differentiation, 
apoptosis and invasion. In line with our results a positive association of gene 
hypermethylation with adverse clinical behaviour in PanNETs has been reported in a 
small number of studies analysing single or few candidate genes [114],[38, 79, 107]. 
Moreover, recent data support the hypothesis that the impairment of epigenetic 
pathways is involved in the pathogenesis of these tumours. Recently, whole-exome 
sequencing of PanNETs demonstrated that the most frequently mutated genes, i.e. 
MEN1, DAXX and ATRX, specify proteins implicated in chromatin remodelling 
suggesting that a primary aberration of epigenetic mechanisms may be a major event in 
PanNETs [34]. Consistent with this concept are reports showing that specific epigenetic 
changes, including hypermethylation of RASSF1A gene and DNA methylation changes 
of the IGF2 Differentially Methylated Region 2, are early and common events in 
PanNETs [127, 128]. Here, we confirm this observation reporting hypermethylation of 
RASSF1A, CASP8 and GSTP1 in most of the tumours examined and we suggest that 
aberrant DNA methylation may be crucial both to development and to progression of 
PanNETs.  
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Besides gene-specific methylation, global CpG methylation has also been characterized 
in the same tumour set providing a link between DNA methylation profiles and CNAs 
in PanNETs.  
 Recent studies showed global hypomethylation in pancreatic and intestinal 
neuroendocrine tumours compared with normal tissue using LINE-1 as a surrogate for 
genome-wide methylation [119, 120]. Although several studies reported that DNA 
hypomethylation correlates with chromosomal instability in a variety of cancers [50, 51, 
129, 130], at present it is poorly understood whether these two alterations are linked in 
PanNETs. A second important and unsolved question is whether genome-wide 
hypomethylation and gene specific hypermethylation are two independent events or if 
they are mechanistically linked in cancer. Attempts to answer this question resulted in 
contradictory findings, with some groups supporting [62, 131, 132] and other refuting 
[133, 134] a link between the two alterations. 
In our study we found a group of highly hypomethylated PanNETs that largely 
overlap with the cluster 2 tumours exhibiting low levels of gene hypermethylation. 
Notably, these cases showed the highest degree of CNAs with six chromosome regions 
more frequently involved in this group compared with the other two clusters. By 
contrast, in average a modest degree of LINE-1 hypomethylation was observed in 
cluster 1 and 3 tumors, most of which showed low levels of CNAs.  
 These findings confirm previous data reported for other cancer sites [135-138] 
and demonstrate that a significant fraction of PanNETs may arise through a possible 
mechanism linking DNA hypomethylation to subsequent chromosomal alterations, due 
the propensity of undermethylated DNA to recombine with a higher frequency than 
normal [139, 140]. Moreover, our results suggest that PanNETs may arise from two 
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main distinct progression pathways: one through a progressive accumulation of 
epigenetic demethylation errors resulting in a variety of chromosomal rearrangements 
and the other one under pressure to de novo methylation of both CpG island promoter 
and repetitive elements and the other. However, overlap in both processes sometimes 
occurs, as observed in four PanNETs in cluster 3 (8% of cases), indicating that a cross-
talk between DNA demethylation and de novo methylation may be hypothesized [132].  
 Regardless of the underlying mechanisms, our results demonstrate that LINE-1 
hypomethylation may increase the malignant potential of PanNETs and is strongly 
associated with shorter survival. Interestingly, multivariate analysis including well-
known clinico-pathologic factors for PanNETs, showed that LINE-1 hypomethylation 
was the only independent significant predictor of outcome. Although this association 
needs to be validated in additional tumor cohorts as well as in large scale clinical 
studies, our results demonstrate that DNA hypomethylation may be considered as an 
additional powerful marker for prognostication of PanNETs. 
In conclusion, our study shows that the combination of global DNA 
demethylation and gene hypermethylation analyses allows to define biologically and 
prognostically distinct subsets of PanNETs. Both alterations can be found in these 
tumors and each one can promote tumorigenesis by independent processes. Further 
delineating the nature and timing of epigenetic hits, which are in principle reversible, is 
potentially highly relevant for epigenetic therapy of PanNETs, and perhaps for tumor 
prevention.
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